Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | VRK2 | Q86Y07 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | VRK1 | Q99986 | 2/20 | 0.35 |
| ▸ | CHUK | O15111 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950838 | 0.80 | PIM1 (0.40) | MKNK1MKNK2KDM4ELMNAHSD17B10 | |
| SCHEMBL3177261 | 0.77 | MAP4K4 (0.47) | MKNK1MKNK2IKBKBKMO | |
| SCHEMBL18554602 | 0.76 | CDC7 (0.40) | MKNK1MKNK2HSD17B10IKBKB | |
| SCHEMBL17054385 | 0.71 | ERN1 (0.73) | ERN1MKNK1MKNK2AKR1C2AKR1C1 | |
| SCHEMBL4945696 | 0.68 | LIPG (0.42) | — | |
| SCHEMBL11907002 | 0.68 | MKNK1 (0.41) | MKNK1MKNK2KDM4E | |
| SCHEMBL11909659 | 0.65 | MKNK1 (0.39) | MKNK1MKNK2 | |
| SCHEMBL11907716 | 0.65 | MKNK1 (0.39) | MKNK1MKNK2KDM4EIKBKB | |
| SCHEMBL1551487 | 0.64 | MKNK1 (0.41) | MKNK1MKNK2CHUKKDM4EIKBKB | |
| SCHEMBL11906973 | 0.63 | IKBKB (0.40) | MKNK1MKNK2HSD17B10RPS6KA3IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893597-B1 | AMPA RECEPTOR POTENTIATORS | LILLY CO ELI (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7393868-B2 | AMPA receptor potentiators | ELI LILLY AND COMPANY (US) | 2008-07-01 | — | — | US | disclosed |
| US-20070142441-A1 | AMPA receptor potentiators | ELI LILLY AND COMPANY | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142441-A1 | AMPA receptor potentiators | GABRE, GRIN1, GRIK2 | ERN1 3645/4885MKNK1 3407/4885MKNK2 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.